Literature DB >> 27625362

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.

Evaren E Page1, Johanna A Kremer Hovinga2, Deirdra R Terrell3, Sara K Vesely3, James N George1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27625362      PMCID： PMC5084608          DOI： 10.1182/blood-2016-06-724161

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941

2.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

3.  Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.

Authors:  Ming Jin; T Charles Casper; Spero R Cataland; Melanie S Kennedy; Shili Lin; Yu J Li; Haifeng M Wu
Journal:  Br J Haematol       Date:  2008-04-07       Impact factor: 6.998

Review 4.  The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Wendy Lim; Sara K Vesely; James N George
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

Review 5.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

Authors:  M Furlan; B Lämmle
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

6.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Authors:  Miguel Hie; Julie Gay; Lionel Galicier; François Provôt; Claire Presne; Pascale Poullin; Guy Bonmarchand; Alain Wynckel; Ygal Benhamou; Philippe Vanhille; Aude Servais; Dominique Bordessoule; Jean-Philippe Coindre; Mohamed Hamidou; Jean-Paul Vernant; Agnès Veyradier; Paul Coppo
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

7.  Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

Authors:  J-P Westwood; H Webster; S McGuckin; V McDonald; S J Machin; M Scully
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

8.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

Review 9.  Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.

Authors:  Y Fujimura; M Matsumoto; A Isonishi; H Yagi; K Kokame; K Soejima; M Murata; T Miyata
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

10.  Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP.

Authors:  Vikram G Pillai; Jialing Bao; Catherine B Zander; Jenny K McDaniel; Palaniappan S Chetty; Steven H Seeholzer; Khalil Bdeir; Douglas B Cines; X Long Zheng
Journal:  Blood       Date:  2016-05-13       Impact factor: 22.113
View more
  16 in total

Review 1.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

Review 2.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

3.  Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Authors:  Sabrina Mariani; Silvia M Trisolini; Saveria Capria; Maria L Moleti; Marta Chisini; Giancarlo Ferrazza; Mahnaz Shafii Bafti; Maria A Limongiello; Eleonora Miulli; Flora Peyvandi; Robin Foà; Anna M Testi
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

Review 4.  Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.

Authors:  Xiaohan Xu; Tienan Zhu; Di Wu; Lu Zhang
Journal:  Clin Rheumatol       Date:  2017-11-13       Impact factor: 2.980

5.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

6.  Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.

Authors:  Teresa Marta Cardesa-Salzmann; Bernhard Stephan; Arne Simon; Rhoikos Furtwängler; Dominik Schöndorf; Sabine Heine; Eyad Torfah; Margaux Lux; Sonja Meyer; Norbert Graf
Journal:  Clin Case Rep       Date:  2022-05-20

7.  Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.

Authors:  Lova Sun; Johnathan Mack; Ang Li; Justine Ryu; Vivek A Upadhyay; Lynne Uhl; Richard M Kaufman; Christopher P Stowell; Walter S Dzik; Robert S Makar; Pavan K Bendapudi
Journal:  Blood Adv       Date:  2019-05-14

8.  Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.

Authors:  Martin Bitzan; Rawan M Hammad; Arnaud Bonnefoy; Watfa Shahwan Al Dhaheri; Catherine Vézina; Georges-Étienne Rivard
Journal:  Pediatr Nephrol       Date:  2018-05-04       Impact factor: 3.714

9.  Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report.

Authors:  Jian Chen; Jing-Xia Jin; Xiao-Fei Xu; Xuan-Xuan Zhang; Xing-Nong Ye; Jian Huang
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

Review 10.  Recent advances in understanding and management of acquired thrombocytopenia.

Authors:  Srikanth Nagalla; Ravindra Sarode
Journal:  F1000Res       Date:  2018-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.